<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47055">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104427</url>
  </required_header>
  <id_info>
    <org_study_id>TG-0054-04</org_study_id>
    <nct_id>NCT02104427</nct_id>
  </id_info>
  <brief_title>PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients</brief_title>
  <official_title>A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Taiwan: Food and Drug Administration, Minisitry of Health and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF
      in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin
      lymphoma or Hodgkin disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the total number of hematopoietic stem cells (HSCs) collected within first four leukapheresis sessions following treatment</measure>
    <time_frame>Day 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of all patients who collected a total number of CD34+ cells over 5.0*10^6 cells/kg within first four leukapheresis sessions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the total number of HSCs collected within five leukapheresis sessions</measure>
    <time_frame>Day 5 to Day 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the average number of leukapheresis sessions required to collect ≧ 2.5*10^6 CD34+ cells/kg and ≧ 5.0*10^6 CD34+ cells /kg</measure>
    <time_frame>Day 5 to Day 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the safety following treatment with TG-0054 when combined with G-CSF</measure>
    <time_frame>one month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>incidence and severity of AE and changes in safety parameters from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the pharmacodynamics (PD) following treatment with TG-0054 when combined with G-CSF</measure>
    <time_frame>Day 5 to Day 9</time_frame>
    <safety_issue>No</safety_issue>
    <description>determine circulating CD34+ cell counts in peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>TG-0054 combined with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. G-CSF: 10 μg/kg/day, administrated via SC injections from  Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-0054 combined with G-CSF</intervention_name>
    <arm_group_label>TG-0054 combined with G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 to 75 years of age inclusive;

          -  Patients with confirmed pathology diagnosis of MM, NHL or HD;

          -  Potential candidate for autologous stem cell transplantation at Investigator's
             discretion;

          -  &gt; 4 weeks since last cycle of chemotherapy prior to the study drug administration;

          -  Total dose of melphalan received ≦ 200 mg in the most recent chemotherapy treatment;

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          -  Recovered from all acute toxic effects of prior chemotherapy at Investigator's
             discretion;

          -  White blood cell (WBC) count ≧ 3.0*10^9/L on screening laboratory assessments;

          -  Absolute neutrophil count ≧ 1.5*10^9/L on screening laboratory assessments;

          -  Platelet count ≧ 100*10^9/L on screening laboratory assessments;

          -  Serum creatinine ≦ 2.2 mg/dL on screening laboratory assessments;

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin
             &lt; 2 x upper limit of normal (ULN) on screening laboratory assessments;

          -  Negative for human immunodeficiency virus (HIV);

          -  Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's
             discretion;

          -  For females, one of the following criteria must be fulfilled:

               1. At least one year post-menopausal, or

               2. Surgically sterile, or

               3. Willing to use a double-barrier method [intrauterine device (IUD) plus condom,
                  spermicidal gel plus condom] of contraception from study Day 1 until 28 days
                  after the last dose of TG-0054;

          -  Males must be willing to use a reliable form of contraception (use of a condom or a
             partner fulfilling the above criteria) from study Day 1 until 28 days after the last
             dose of TG-0054;

          -  Able to provide the signed informed consent.

        Exclusion Criteria:

          -  Received radiation therapy to the pelvis;

          -  Received &gt; 6 cycles of lenalidomide;

          -  Evidence of bone marrow involvement of lymphoma in NHL patients;

          -  Failed previous stem cell collection [failed to collect 2.0*10^6 CD34+ cells/kg
             within 4 leukapheresis sessions after receiving granulocyte colony-stimulating factor
             (G-CSF)];

          -  Patients who have undergone previous stem cell transplantation procedure;

          -  Received G-CSF within 2 weeks prior to the study drug administration;

          -  History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or
             squamous cell carcinoma of the skin;

          -  History of other hematologic disorders including bleeding or thromboembolic disease
             being treated with anti-coagulant;

          -  History of poor and uncontrollable cardiovascular or pulmonary disease such as
             myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or
             Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two
             times a year due to underlying disease;

          -  Diagnosis of sickle cell anemia or documented sickle cell trait;

          -  Patients with proliferative retinopathy;

          -  Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at
             Investigator's discretion;

          -  Any infection required antibiotic treatment or unexplained fever above 38 °C within 3
             days prior to dosing;

          -  Pregnant or breast-feeding;

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study;

          -  Received any other investigational drug within 1 month before entering the study;

          -  Received prior treatment with TG-0054 but withdrew early from this study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen-En Tsai, MD</last_name>
    <phone>886-2-8177-7072</phone>
    <phone_ext>1211</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael M Schuster, MD</last_name>
      <phone>631-444-3577</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>March 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
